MarginsXMarginsX
Home › Markets › Health Care › ARMP

Armata Pharmaceuticals Inc. (ARMP)

ARMP trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.99
-22.74% on the day
Market cap
$111.2M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerARMP on NYSE
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000921114

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
8.3 months
$18.3M cash at September 30, 2026
Share count, 1 year
+2.4%
2025-11-04 to 2026-11-06 · +2.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These circumstances raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$18.3M cash; operating cash flow -$6.7M a quarter.Report 2026-09-30
Shares outstanding37,192,632 (2026-11-06); 36,329,842 a year earlier; 36,146,574 three years earlier.Cover page 2026-11-06
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2025-12-01
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed$54.9M-$5.5M$18.3M$94.3MNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed$74.1M-$8.7M$24.0M$163.9MNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$115.3M-$5.8M$4.8M$254.9MNeeds four quarters10-Q 2026-05-13
Q4 2025
2025-12-31
Not filed-$124.3M-$6.7M$8.7M$153.9MNeeds four quarters10-K 2026-03-25
Q3 2025
2025-09-30
Not filed-$26.7M-$4.3M$14.8M$48.1MNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$16.3M-$7.2M$4.3M$33.4MNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$6.5M-$7.6M$11.7M$27.7MNeeds four quarters10-Q 2026-05-13
Q4 2024
2024-12-31
Not filed$2.6M-$7.9M$9.3M$32.9MNeeds four quarters10-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+10.3%
1 month+24.8%
3 months-19.7%
Year to date-38.4%
1 year-39.3%
From 52-week high-73.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ZURAZura Bio Limited$1.08-12.90%$104.0M
CMPXCompass Therapeutics Inc.$0.6615-14.51%$119.1M
LENZLENZ Therapeutics Inc.$3.82-7.51%$120.0M
VYGRVoyager Therapeutics Inc.$1.63-5.78%$101.4M
MOLNMolecular Partners AG$2.70-8.21%$101.2M
CRDLCardiol Therapeutics Inc. Class A Common Shares$0.9798-2.02%$125.1M
ENGNenGene Therapeutics Inc.$1.89-21.58%$126.7M
OTLKOutlook Therapeutics Inc.$0.3960-4.12%$96.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier